litlas
Log inCreate account

Priya Rastogi

Active 2005–2025

79
Papers
22,874
Citations
45
h-index
75
i10-index

Citations

Citations per year for Priya Rastogi1981: 1 citations1982: 2 citations1999: 1 citations2004: 1 citations2005: 2 citations2006: 13 citations2007: 24 citations2008: 37 citations2009: 32 citations2010: 49 citations2011: 48 citations2012: 52 citations2013: 77 citations2014: 95 citations2015: 160 citations2016: 157 citations2017: 127 citations2018: 131 citations2019: 590 citations2020: 739 citations2021: 882 citations2022: 979 citations2023: 821 citations2024: 1,333 citations2025: 709 citations2026: 19 citations1983–1998: no citations, so these years are not shown2000–2003: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,201 citing papers, 22.7% of this breakdownChina: 928 citing papers, 9.6% of this breakdownItaly: 721 citing papers, 7.4% of this breakdownGermany: 527 citing papers, 5.4% of this breakdownUnited Kingdom: 486 citing papers, 5% of this breakdownSpain: 418 citing papers, 4.3% of this breakdownFrance: 382 citing papers, 3.9% of this breakdownCanada: 375 citing papers, 3.9% of this breakdownBelgium: 287 citing papers, 3% of this breakdownSwitzerland: 284 citing papers, 2.9% of this breakdownAustralia: 249 citing papers, 2.6% of this breakdownNetherlands: 239 citing papers, 2.5% of this breakdown
0%22.7%Other 26.8%

Institutions

Fields

  • Medicine53.8%
  • Biochemistry, Genetics and Molecular Biology40.8%
  • Computer Science1.4%
  • Immunology and Microbiology1.4%
  • Engineering0.7%
  • Materials Science0.5%
  • Other1.4%

Topics

  • Breast Cancer Treatment Studies14.8%
  • HER2/EGFR in Cancer Research10%
  • Advanced Breast Cancer Therapies6.1%
  • Breast Lesions and Carcinomas4.7%
  • Cancer Treatment and Pharmacology3.7%
  • Cancer Immunotherapy and Biomarkers2.9%
  • Other57.8%

Coauthors

All papers

Open in search
  1. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    Authors: Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P. Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa, Sandra M. Swain, Tatiana M. Prowell, Sibylle Loibl, D. Lawrence Wickerham, Jan Bogaerts, José Baselga, Charles M. Perou, Gideon M. Blumenthal, Jens‐Uwe Blohmer, Eleftherios P. Mamounas, Jonas Bergh, Semiglazov Vf, Robert Justice, Holger Eidtmann, Soonmyung Paik, Martine Piccart, Rajeshwari Sridhara, Peter A. Fasching, Leen Slaets, Shenghui Tang, Bernd Gerber, Charles E. Geyer, Richard Pazdur, Nina Ditsch, Priya Rastogi, W. Eiermann, Gϋnter von Minckwitz - The Lancet 2014 cited by 4,710

  2. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

    Authors: Gϋnter von Minckwitz, Chiun‐Sheng Huang, Max S. Mano, Sibylle Loibl, Eleftherios P. Mamounas, Michael Untch, Norman Wolmark, Priya Rastogi, Andreas Schneeweiß, Andrés Redondo, Hans Holger Fischer, William Jacot, Alison Conlin, Claudia Arce-Salinas, Irene Wapnir, Christian Jackisch, Michael P. DiGiovanna, Peter A. Fasching, John Crown, P Wülfing, Zhimin Shao, Elena Rota Caremoli, Haiyan Wu, Lisa H. Lam, David Tesarowski, Melanie C. Smitt, Hannah Douthwaite, Stina Mui Singel, Charles E. Geyer - New England Journal of Medicine 2018 cited by 2,618

  3. Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer

    Authors: Andrew Tutt, Judy E. Garber, Bella Kaufman, Giuseppe Viale, Debora Fumagalli, Priya Rastogi, Richard D. Gelber, Evandro de Azambuja, Anitra Fielding, Judith Balmaña, Susan M. Domchek, Karen A. Gelmon, Simon J. Hollingsworth, Larissa A. Korde, Barbro Linderholm, Hanna Bandos, Elżbieta Senkus, Jennifer M. Suga, Zhimin Shao, Andrew W. Pippas, Zbigniew Nowecki, Tomasz Huzarski, Patricia A. Ganz, Peter C. Lucas, Nigel Baker, Sibylle Loibl, Robin McConnell, Martine Piccart, Rita K. Schmutzler, Guenther G. Steger, Joseph P. Costantino, Amal Arahmani, Norman Wolmark, Eleanor McFadden, Vassiliki Karantza, Sunil R. Lakhani, Greg Yothers, Christine Campbell, Charles E. Geyer - New England Journal of Medicine 2021 cited by 1,665

  4. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

    Authors: Stephen Johnston, Masakazu Toi, Joyce O’Shaughnessy, Priya Rastogi, Mario Campone, Patrick Neven, Chiun‐Sheng Huang, Jens Huober, Georgina Garnica Jaliffe, İrfan Çiçin, Sara M. Tolaney, Matthew P. Goetz, Hope S. Rugo, Elżbieta Senkus, Laura Testa, Lucia Del Mastro, Chikako Shimizu, Ran Wei, Ashwin Shahir, Marı́a Jesús Muñoz, Belén San Antonio, Valérie André, Nadia Harbeck, Miguel Martín - The Lancet Oncology 2022 cited by 566

  5. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

    Authors: Stephen R. D. Johnston, Nadia Harbeck, Roberto Hegg, Masakazu Toi, Miguel Martin, Zhi Min Shao, Qing Yuan Zhang, Jorge Luis Martinez Rodriguez, Mario Campone, Erika Hamilton, Joohyuk Sohn, Valentina Guarneri, Morihito Okada, Frances Boyle, Patrick Neven, Javier Cortés, Jens Huober, Andrew Wardley, Sara M. Tolaney, Irfan Cicin, Ian C. Smith, Martin Frenzel, Desirée Headley, Ran Wei, Belen San Antonio, Maarten Hulstijn, Joanne Cox, Joyce O’Shaughnessy, Priya Rastogi - Journal of Clinical Oncology 2020 cited by 986

  6. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

    Authors: Kevin Kalinsky, William E. Barlow, Julie R. Gralow, Funda Meric-Bernstam, Kathy S. Albain, Daniel F. Hayes, Nancy U. Lin, Edith A. Perez, Lori J. Goldstein, Stephen K.L. Chia, Sukhbinder Dhesy-Thind, Priya Rastogi, Emilio Alba, Suzette Delaloge, Miguel Martin, Catherine M. Kelly, Manuel Ruiz-Borrego, Miguel Gil-Gil, Claudia H. Arce-Salinas, Etienne G.C. Brain, Eun-Sook Lee, Jean-Yves Pierga, Begoña Bermejo, Manuel Ramos-Vazquez, Kyung-Hae Jung, Jean-Marc Ferrero, Anne F. Schott, Steven Shak, Priyanka Sharma, Danika L. Lew, Jieling Miao, Debasish Tripathy, Lajos Pusztai, Gabriel N. Hortobagyi - New England Journal of Medicine 2021 cited by 832

  7. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Authors: Charles E. Geyer, Judy E. Garber, Richard D. Gelber, Greg Yothers, Manuel Taboada, L. Ross, Priya Rastogi, Karen Cui, Amal Arahmani, Gursel Aktan, Anne Armstrong, Mónica Arnedos, Judith Balmaña, Jonas Bergh, Judith M. Bliss, Suzette Delaloge, Susan M. Domchek, Andrea Eisen, F. Elsafy, L.E. Fein, Anitra Fielding, James M. Ford, Sue Friedman, Karen A. Gelmon, Luca Gianni, Michael Gnant, Simon J. Hollingsworth, Seock‐Ah Im, Agnes Jager, Oskar T. Johannsson, Sunil R. Lakhani, W Janni, Barbro Linderholm, T.-W. Liu, Niklas Loman, Larissa A. Korde, Sibylle Loibl, Peter C. Lucas, Frederik Marmé, E. Martinez de Dueñas, Robin McConnell, Kelly‐Anne Phillips, Martine Piccart, Giovanna Rossi, Rita K. Schmutzler, Elżbieta Senkus, Zhi-Ming Shao, Priyanka Sharma, Christian F. Singer, Tanja Španić, Elmar Stickeler, Masakazu Toi, Tiffany A. Traina, Giuseppe Viale, Gabriele Zoppoli, Y.H. Park, Rinat Yerushalmi, Huan Yang, D. Pang, Kyung Hae Jung, Audrey Mailliez, Zhaoqing Fan, Isabelle Tennevet, J. Zhang, T. Nagy, Gabe S. Sonke, Qiuhong Sun, Marina Parton, Marco Colleoni, Marcus Schmidt, Adam Brufsky, W. Razaq, Bella Kaufman, David Cameron, Christine Campbell, Andrew Tutt, P. Sevelda, Ferdinand Haslbauer, Monika Penzinger, Leopold Öhler, Christoph Tinchon, Richard Greil, Sonja Heibl, Rupert Bartsch, Viktor Wette, Christian F. Singer, Claudia Pasterk, Ruth Helfgott, Gunda Pristauz-Telsnigg, Herbert Stöger, A. Weltermann, Daniel Egle, I. Thiel, David Fuchs, Holger Rumpold, Kathrin Strasser‐Weippl, Beate Rautenberg, Volkmar Müller, Marcus Schmidt, Stefan Paepke and 509 more - Annals of Oncology 2022 cited by 447

  8. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

    Authors: Sibylle Loibl, Joyce O’Shaughnessy, Michael Untch, William M. Sikov, Hope S. Rugo, Mark D. McKee, Jens Huober, Mehra Golshan, Gϋnter von Minckwitz, David Maag, Danielle Sullivan, Norman Wolmark, Kristi McIntyre, José Ponce, Otto Metzger, Priya Rastogi, W. Fraser Symmans, Xuan Liu, Charles E. Geyer - The Lancet Oncology 2018 cited by 771

  9. Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer

    Authors: Pamela J. Goodwin, Bingshu E. Chen, Karen A. Gelmon, Timothy J. Whelan, Marguerite Ennis, Julie Lemieux, Jennifer A. Ligibel, Dawn L. Hershman, Ingrid A. Mayer, Timothy J. Hobday, Judith M. Bliss, Priya Rastogi, Manuela Rabaglio, Som D. Mukherjee, John R. Mackey, Vandana G. Abramson, Conrad D. Oja, Robert Wesolowski, Alastair M. Thompson, Daniel Rea, Paul M. Stos, Lois E. Shepherd, Vuk Stambolic, Wendy R. Parulekar - JAMA 2022 cited by 223

  10. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+

    Authors: Louis Fehrenbacher, Reena S. Cecchini, Charles E. Geyer, Priya Rastogi, Joseph P. Costantino, James N. Atkins, John Crown, Jonathan Polikoff, Jean-François Boileau, Louise Provencher, Christopher Stokoe, Timothy D. Moore, André Robidoux, Patrick J. Flynn, Virginia F. Borges, Kathy S. Albain, Sandra M. Swain, Soonmyung Paik, Eleftherios P. Mamounas, Norman Wolmark - Journal of Clinical Oncology 2019 cited by 420

  11. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

    Authors: Nadia Harbeck, Priya Rastogi, Miguel Martín, Sara M. Tolaney, Zhimin Shao, Peter A. Fasching, Chiun‐Sheng Huang, Georgina Garnica Jaliffe, A. Tryakin, Matthew P. Goetz, Hope S. Rugo, Elżbieta Senkus, Laura Testa, Mariette Andersson, Kenji Tamura, Lucia Del Mastro, Guenther G. Steger, Hans Kreipe, Roberto Hegg, Joohyuk Sohn, Valentina Guarneri, Javier Cortés, E.P. Hamilton, Valérie André, Ran Wei, Susana Barriga, S. Sherwood, Tammy Forrester, Montserrat Muñoz-Mateu, Ashwin Shahir, Belén San Antonio, Sarah C. Nabinger, Masakazu Toi, Stephen Johnston, Joyce O’Shaughnessy, M.M. Jimenez, Stephen Johnston, F. Boyle, Guenther G. Steger, Patrick Neven, Zefei Jiang, Mario Campone, Jens Huober, Chikako Shimizu, I. Cicin, Andrew Wardley, Sara M. Tolaney, Gonzalo Gómez Abuin, J. J. Zarba, Elgene Lim, P. Sant, Naishun Liao, Bo Christiansen, Natalja Eigėlienė, J. Martin-Babau, Johannes Ettl, D. Mavroudis, Joanne Chiu, Katalin Boér, R. Nagarkar, Shani Paluch–Shimon, Luca Moscetti, Yoshiatsu Sagara, S.-B. Kim, Rui M. B. Maciel, Vivianne C. G. Tjan‐Heijnen, Reuben Broom, Aleksandra Łacko, M. Schenker, Nikita Volkov, Yoon Sim Yap, M.A. Coccia-Portugal, J. Ángel García Sáenz, Anne Andersson, Tai-Jong Chao, Erhan Gökmen, Hakan Harputluoğlu, O. Berzoy, Debra A. Patt, Heather L. McArthur, Helen K. Chew, Pavani Chalasani, Peter A. Kaufman, Karen L. Tedesco, Stephanie L. Graff - Annals of Oncology 2021 cited by 378

  12. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

    Authors: Priya Rastogi, Joyce O’Shaughnessy, Miguel Martín, Frances Boyle, Javier Cortés, Hope S. Rugo, Matthew P. Goetz, Erika Hamilton, Chiun‐Sheng Huang, Elżbieta Senkus, A. Tryakin, İrfan Çiçin, Laura Testa, Patrick Neven, Jens Huober, Zhimin Shao, Ran Wei, Valérie André, María del Mar Muñoz, Belén San Antonio, Ashwin Shahir, Nadia Harbeck, Stephen Johnston - Journal of Clinical Oncology 2024 cited by 204

  13. Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

    Authors: Priya Rastogi, Stewart Anderson, Harry D. Bear, Charles E. Geyer, Morton S. Kahlenberg, André Robidoux, Richard G. Margolese, James L. Hoehn, Victor G. Vogel, Shaker R. Dakhil, Deimante Tamkus, Karen King, Eduardo R. Pajon, Mary Wright, Jean Robert, Soonmyung Paik, Eleftherios P. Mamounas, Norman Wolmark - Journal of Clinical Oncology 2008 cited by 1,803

  14. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial

    Authors: Charles E. Geyer, William M. Sikov, Jens Huober, Hope S. Rugo, Norman Wolmark, J. O’Shaughnessy, David Maag, Michael Untch, Mehra Golshan, José Ponce, Otto Metzger, Martin Dunbar, W. Fraser Symmans, Priya Rastogi, Joohyuk Sohn, Robyn R. Young, Gail S. Wright, C. Harkness, Kristi McIntyre, Denise A. Yardley, Sibylle Loibl - Annals of Oncology 2022 cited by 219

  15. Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831

    Authors: Edith A. Perez, Edward H. Romond, Vera J. Suman, Jong‐Hyeon Jeong, George W. Sledge, Charles E. Geyer, Silvana Martino, Priya Rastogi, Julie R. Gralow, Sandra M. Swain, Eric P. Winer, Gerardo Colón‐Otero, Nancy E. Davidson, E. Mamounas, Jo Anne Zujewski, Norman Wolmark - Journal of Clinical Oncology 2014 cited by 998

  16. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study

    Authors: Hope S. Rugo, Joyce O’Shaughnessy, F Boyle, Masakazu Toi, Reuben Broom, Isabel Blancas, M. Gumus, Toshinari Yamashita, Y-H Im, Priya Rastogi, Flora Zagouri, Changhoon Song, Mario Campone, Belén San Antonio, Ashwin Shahir, Maarten Hulstijn, Jacqueline Brown, Annamaria H. Zimmermann, R. Wei, Stephen Johnston, Mattea Reinisch, Sara M. Tolaney - Annals of Oncology 2022 cited by 128

  17. Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

    Authors: Marion van Mackelenbergh, Sibylle Loibl, Michael Untch, Marc Buyse, Charles E. Geyer, Luca Gianni, Andreas Schneeweiß, PierFranco Conte, Martine Piccart, Hervé Bonnefoi, Christian Jackisch, Valentina Nekljudova, Gong Tang, Pinuccia Valagussa, Colin Neate, Richard D. Gelber, Coralie Poncet, Pierre Squifflet, Everardo D. Saad, Dominik Heinzmann, Carsten Denkert, Priya Rastogi, Javier Cortés, Valentina Guarneri, Evandro de Azambuja, David Cameron, Gustavo Ismael, Norman Wolmark, Patricia Cortazar, on behalf of the CTNeoBC project - Journal of Clinical Oncology 2023 cited by 96

  18. Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

    Authors: Edward H. Romond, Jong‐Hyeon Jeong, Priya Rastogi, Sandra M. Swain, Charles E. Geyer, Michael S. Ewer, Vikas Rathi, Louis Fehrenbacher, Adam Brufsky, Catherine A. Azar, Patrick J. Flynn, John L. Zapas, Jonathan Polikoff, Howard M. Gross, David D. Biggs, James N. Atkins, Elizabeth Tan-Chiu, Ping Zheng, Greg Yothers, Eleftherios P. Mamounas, Norman Wolmark - Journal of Clinical Oncology 2012 cited by 519

  19. Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer

    Authors: Charles E. Geyer, M. Untch, Chiun‐Sheng Huang, Max S. Mano, Eleftherios P. Mamounas, Norman Wolmark, Priya Rastogi, Andreas Schneeweiß, Andrés Redondo, Hans Holger Fischer, Véronique D’Hondt, Alison Conlin, Valentina Guarneri, Irene Wapnir, Christian Jackisch, Claudia Arce-Salinas, Peter A. Fasching, Michael P. DiGiovanna, John Crown, Pia Wuelfing, Zhimin Shao, Elena Rota Caremoli, Hervé Bonnefoi, Bryan T. Hennessy, Ljiljana Stamatović, Hugo Castro‐Salguero, Adam Brufsky, Adam Knott, Asna Siddiqui, Chiara Lambertini, Thomas Boulet, Beatrice Nyawira, Eleonora Restuccia, Sibylle Loibl - New England Journal of Medicine 2025 cited by 115

  20. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial

    Authors: André Robidoux, Gong Tang, Priya Rastogi, Charles E. Geyer, Catherine A. Azar, James N. Atkins, Louis Fehrenbacher, Harry D. Bear, Louis Baez-Diaz, Shakir Sarwar, Richard G. Margolese, William B. Farrar, Adam Brufsky, Henry R. Shibata, Hanna Bandos, Soonmyung Paik, Joseph P. Costantino, Sandra M. Swain, Eleftherios P. Mamounas, Norman Wolmark - The Lancet Oncology 2013 cited by 386

  21. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Eleftherios P. Mamounas, Hanna Bandos, Barry C. Lembersky, Jong‐Hyeon Jeong, Charles E. Geyer, Priya Rastogi, Louis Fehrenbacher, Mark L. Graham, Stephen Chia, Adam Brufsky, Janice M. Walshe, Gamini S. Soori, Shaker R. Dakhil, Thomas E. Seay, James L. Wade, Edward C. McCarron, Soonmyung Paik, Sandra M. Swain, D. Lawrence Wickerham, Norman Wolmark - The Lancet Oncology 2018 cited by 163

  22. Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31

    Authors: Elizabeth Tan-Chiu, Greg Yothers, Edward H. Romond, Charles E. Geyer, Michael S. Ewer, Deborah Keefe, Richard P. Shannon, Sandra M. Swain, Ann Brown, Louis Fehrenbacher, Victor G. Vogel, Thomas E. Seay, Priya Rastogi, Eleftherios P. Mamounas, Norman Wolmark, John Bryant - Journal of Clinical Oncology 2005 cited by 807

  23. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer

    Authors: Otto Metzger, Daniel G. Stover, Sarah Asad, Peter Ansell, Mark A. Watson, Sibylle Loibl, Charles E. Geyer, Junu Bae, Katharine A. Collier, Mathew Cherian, Joyce O’Shaughnessy, Michael Untch, Hope S. Rugo, Jens Huober, Mehra Golshan, William M. Sikov, Gϋnter von Minckwitz, Priya Rastogi, David Maag, Norman Wolmark, Carsten Denkert, W. Fraser Symmans - JAMA Oncology 2021 cited by 75

  24. Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–Human Epidermal Growth Factor Receptor 2 Therapy

    Authors: Pierre Squifflet, Everardo D. Saad, Sibylle Loibl, Marion van Mackelenbergh, Michael Untch, Priya Rastogi, Luca Gianni, Andreas Schneeweiß, PierFranco Conte, Martine Piccart, Hervé Bonnefoi, Christian Jackisch, Valentina Nekljudova, Gong Tang, Pinuccia Valagussa, Colin Neate, Richard D. Gelber, Coralie Poncet, Dominik Heinzmann, Carsten Denkert, Charles E. Geyer, Javier Cortés, Valentina Guarneri, Evandro de Azambuja, David Cameron, Gustavo Ismael, Norman Wolmark, Patricia Cortazar, Marc Buyse, on behalf of the CTNeoBC Project - Journal of Clinical Oncology 2023 cited by 55